Biotechnology - Anti-virals, Asia-Pacific

Filter

Current filters:

Anti-viralsAsia-Pacific

Popular Filters

I-MAK challenges Gilead sofosbuvir patent in India

I-MAK challenges Gilead sofosbuvir patent in India

25-11-2013

USA-based advocacy group the Initiative for Medicines, Access & Knowledge last week filed a challenge…

Anti-viralsAsia-PacificBiotechnologyGilead SciencesPatentssofosbuvirSovaldi

New Zealand consults on Victrelis listing and some Pegasys amendments

19-07-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list boceprevir…

Anti-viralsAsia-PacificBiotechnologyMerck & CoPegasysPharmaceuticalRegulationRocheVictrelis

BioLineRx collaborates with Chinese firm on hep C drug BL-8030

11-06-2013

Israeli drug developer BioLineRx (TASE: BLRX) has signed an out-licensing agreement with Jiangsu Chia-tai…

Anti-viralsAsia-PacificBioLineRxBiotechnologyBL-8030Chia-tai Tianqing PharmaceuticalLicensingPharmaceutical

Third deal for Ascletis, which gains China market rights from Janssen to a clinical stage HIV protease inhibitor

01-05-2013

USA and China-based biotech firm Ascletis Pharmaceuticals says it has licensed development, manufacturing…

Anti-viralsAscletis PharmaceuticalsAsia-PacificBiotechnologyJanssenJohnson & JohnsonLicensingTMC310911

Roche teams up with Ascletis on hep C treatments for China

15-04-2013

Roche (ROG: SIX) has entered a collaboration with Ascletis Pharmaceuticals, a USA- and China-based biotech…

Anti-viralsAscletis PharmaceuticalsAsia-PacificBiotechnologydanoprevirLicensingMarkets & MarketingPharmaceuticalResearchRoche

Japan Tobacco files for Japanese approval of elvitegravir

11-12-2012

Japan Tobacco (TSE:2914) has filed a New Drug Application for marketing approval of a novel anti-HIV…

Anti-viralsAsia-PacificBiotechnologyelvitegravirGilead SciencesJapan TobaccoPharmaceuticalRegulationTorii Pharma

New Zealand to fund Gilead's Atripla and Truvada

27-11-2012

New Zealand's Pharmaceutical Management Agency PHARMAC says that, effective December 1, it will fund…

Anti-viralsAsia-PacificAtriplaBiotechnologyFinancialGilead SciencesPharmaceuticalRegulationTruvada

Gilead HIV drugs Atripla and Truvada to be listed in New Zealand

13-11-2012

Following a consultation, New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval…

Anti-viralsAsia-PacificAtriplaBiotechnologyGilead SciencesPharmaceuticalPricingRegulationTruvada

Back to top